Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Light therapy shows promise in tough mesothelioma trial

NCT ID NCT02662504

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested whether adding intrapleural photodynamic therapy (PDT) to standard surgery and chemotherapy is safe and feasible for patients with malignant pleural mesothelioma. Six participants received a light-sensitive drug followed by laser light inside the chest cavity during surgery. The goal was to see if patients could complete the full treatment without severe side effects. Results will help decide if a larger trial comparing PDT to standard care is warranted.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
porfimer sodium (Photofrin) with laser light
What this could lead to
If successful, this could lead to a larger trial testing whether adding photodynamic therapy to standard surgery and chemotherapy improves survival for mesothelioma patients.
What could go wrong
This is a very small pilot study (6 participants) focused on feasibility and safety, not effectiveness. The treatment is complex and carries risks from surgery, chemotherapy, and light sensitivity. Results may not apply to all mesothelioma types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

6 people

The number who actually took part.

Started

Jan 2016

Finished

Mar 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * histologically-proved epithelioid malignant pleural mesothelioma (MPM) on biopsies obtained before eP/D surgery * tumor stage: no tumor extension to controlateral lung, mediastinum, peritoneum or myocardium (\<T4); mediastinal lymph nodes extension: cN2 but no bulky N2 or N3), no metastasis (M0) * Performance status WHO PS 0-1 * patients fit to have surgery (eP/D) and chemotherapy (cisplatin-pemetrexed), based on clinical examination, complete normal biological work-up, full assessment by cardiac and pulmonary function tests. Predicted post-surgical values should be sufficient for normal daily life: FEV1\>40%; pre-surgical DLCO\>50% predicted value and VO2max \>15 ml/min/kg; (left ventricular) cardiac function \>50% and no significant pulmonary artery hypertension * written informed consent must be obtained before inclusion and randomization Exclusion Criteria: * Another histologic subtype than epithelioid MPM at the time of diagnosis * Bulky N2, N3 and/or M1 stage (UICC/IMIG 1995) * prior chemotherapy for mesothelioma * prior radiotherapy of thorax, neck or upper abdomen * other malignancy treated within 5 years, except basal cell carcinoma or in situ carcinoma of the cervix * contra-indication for MPM surgery or chemotherapy (cisplatin and pemetrexed): cardiac failure, pulmonary hypertension, liver or kidney dysfunction (GFR\<60 ml/min), uncontrolled infection, previous major neurotoxicity or ototoxicity,... or other severe condition according to the investigator * pregnancy or breast feeding * contra-indication for porfimer sodium (Photofrin): porphyria or known hypersensitivity to porphyrins, severe hepatic impairment, tracheo-oesophageal or broncho-oesophageal fistula, suspected erosion of major blood vessels due to risk of massive, potentially fatal haemorrhage * A previous talc pleurodesis during diagnostic thoracoscopy is NOT an exclusion criteria but talc on mediastinal pleura should be avoided to not keep away from eP/D.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epithelioid malignant pleural mesothelioma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHRU de Lille Hôpital Calmette

    Lille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.